Stoop Thomas F, Javed Ammar A, Oba Atsushi, Koerkamp Bas Groot, Seufferlein Thomas, Wilmink Johanna W, Besselink Marc G
Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands.
Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, Netherlands; Cancer Center Amsterdam, Amsterdam, Netherlands; Division of Surgical Oncology, Department of Surgery, New York University Medical Center, New York, NY, USA.
Lancet. 2025 Apr 5;405(10485):1182-1202. doi: 10.1016/S0140-6736(25)00261-2.
Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.
胰腺癌通常是一种致命疾病，其肿瘤生物学行为具有侵袭性，常表现为非特异性症状。中位生存期约为4个月，5年生存率为13%。对于患有家族性胰腺癌、特定突变以及高危导管内乳头状黏液性肿瘤的个体，建议进行监测，因为他们患胰腺癌的风险很高。化疗联合手术切除仍然是治疗的基石。然而，只有一小部分患者适合手术。多药化疗改善了转移性疾病患者姑息治疗的生存率，（新）辅助治疗和诱导治疗也改善了边界可切除和局部晚期胰腺癌患者的生存率。鉴于预计到2030年胰腺癌将成为癌症相关死亡的第二大主要原因，迫切需要新的治疗方法。
